We scan new podcasts and send you the top 5 insights daily.
Marshall Fordyce says Vera’s 428-patient phase 3 trial had placebo volunteers losing 5–10% of kidney function yearly. Vera persuaded FDA to analyze early, showed Trutacna helped, and switched every placebo volunteer to the drug rather than waiting for more decline. That makes patient-centricity a trial-access and accountability mechanism.
Instead of stopping a trial early for success—which regulators may restrict—a high-confidence early signal provides immense value as business intelligence. This allows sponsors to de-risk and accelerate planning for subsequent phases months earlier, creating millions in value by reducing the gap between Phase 2 and 3.
In ovarian cancer trials, many patients in the placebo group later receive a PARP inhibitor. This crossover "pollutes" the data, making it difficult to prove a statistically significant overall survival benefit for frontline PARP maintenance, despite its clear effectiveness.
While the financial losses from failed trials are staggering, the most devastating outcome is the human cost. Patients, especially those on placebo, invest years of their lives, suffer, and sometimes die while participating in trials that ultimately fail, when they could have been exploring other treatment options.
While the INDEPENDENCE trial focused on complete transfusion independence, a key takeaway is that less stringent but highly valuable patient outcomes are crucial. Achieving a 50% reduction in transfusion needs offers a significant quality-of-life improvement. This suggests future trials should incorporate more flexible, patient-centric secondary endpoints that reflect real-world clinical benefits.
With effective obesity drugs widely available, patients in trials quickly realize they are on placebo and drop out, compromising data integrity. This is pushing the industry toward using existing drugs as the control arm, making trials more complex and expensive but yielding more realistic, comparative data on efficacy and tolerability.
Running an unusually long, two-year Phase 2 trial allowed Vera to demonstrate stabilization of GFR, a hard kidney function endpoint. This robust, long-term data was crucial for de-risking their Phase 3 program and ultimately securing a coveted Breakthrough Therapy Designation from the FDA, accelerating their path to market.
Including patient advocates in decision-making is critical but can create strategic conflicts. A patient group advocated for unblinding a trial early for faster access, a move that pleased the market but was criticized by regulators for potentially compromising long-term survival data.
Fordyce says Vera’s patient focus started before trials by choosing autoimmune disease and a mechanism aimed at inadequate standard of care. He points to steroid side effects—acute and chronic—as a real patient problem. He argues listening to patients reveals these harms and should shape target selection, not just marketing.
In the ASCENT-07 trial, investigators may have prematurely switched patients from the standard chemotherapy arm to superior, commercially available ADCs at the first hint of progression. This real-world practice can mask an experimental drug's true benefit on progression-free survival.
Praxis Interactive's essential tremor drug succeeded in Phase 3 despite an earlier data monitoring committee (DMC) recommendation to stop for futility. This rare outcome shows that interim analyses on a small fraction of patients can be misleading due to high variance, and continuing a trial against DMC advice can be a winning strategy.